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Lymphadenopathy is common, affecting patients of all ages. The current referral pattern for investigating patients with
lymphadenopathy varies widely with no universally practised pathway. Our institution set up a lymph node diagnostic clinic (LNDC)
accepting direct referrals from primary care physicians. Details of clinical presentation and investigations were recorded prospectively.
Between December 1996 and July 2001, 550 patients were referred (M: 203; F:347). The median age was 40 years (range 14–90).
The median time between initial referral and the first clinic visit was 6 days. Of 95 patients diagnosed to have malignant diseases, the
median time from the first clinic visit to reaching malignant diagnosis was 15 days. Multivariate logistic regression analysis identified five
significant predictors for malignant nodes: male gender (risk ratio (RR)¼ 2.72; 95% confidence interval (CI): 1.63–4.56), increasing
age (RR¼ 1.05; 95% CI: 1.04–1.07), white ethnicity (RR¼ 3.01; 95% CI: 1.19–7.6) and sites of lymph nodes: supraclavicular region
(RR¼ 3.72; 95% CI: 1.52–9.12) and X2 regions of lymph nodes (RR¼ 6.41; 95% CI: 2.82–14.58). Ultrasound and fine-needle
aspiration cytology of palpable lymph nodes were performed in 154 and 289 patients, respectively. An accuracy of 97 and 84% was
found, respectively. In conclusion, a multidisciplinary lymph node diagnostic clinic enables a rapid, concerted approach to a common
medical problem and patients with malignant diseases were diagnosed in a timely fashion.
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Lymphadenopathy (LA) is common and affects patients of all ages.
An annual incidence of 0.6–0.7% has been estimated for the
general population (Allhiser et al, 1981; Fijten and Blijham, 1988).
Patients with lymphadenopathy present to a wide range of medical
specialties. When physicians are faced with these patients, the
critical tasks are to differentiate benign from malignant lymph
nodes, to identify serious medical conditions that require specialist
care, and to reassure patients with benign reactive lymphadeno-
pathy or self-limiting diseases.
The possibility of malignancy raises the most concern among
patients and health care professionals. Prompt referral for
definitive investigations and treatment cannot be overstated, as
cancer is perhaps the disease people fear most. Despite the
incidences of many cancers being broadly similar in England
compared with other European countries and the USA, the
corresponding survival rates are poorer (Table 1) (Office for
National Statistics, 1999; Ries et al, 2001). To address this problem,
the British government proposed, in September 2000, the National
Health Service (NHS) Cancer Plan to provide a comprehensive
strategy for bringing together prevention, screening, diagnosis,
treatment and care for cancer to improve survival (Department of
Health, 2000b). The current guideline recommends all patients
with lymphadenopathy of more than 1 cm in size persisting for 6
weeks to be referred urgently for further evaluation (Department
of Health, 2000a).
Apart from cancer, there are also other medical conditions
presenting with LA that will require urgent medical attention. This
would include infections such as tuberculosis (TB) and human
immunodeficiency virus (HIV), both of which pose an important
public health problem. In addition, immune-induced injury
disorders such as systemic lupus erythematosus, sarcoidosis and
rheumatoid arthritis will also require specialist care.
Even after the general practitioner (GP) has decided to refer a
patient with lymphadenopathy for definitive diagnostic assess-
ment, the referral pattern to specialists varies at the present time.
Some patients may be referred to general surgeons for biopsy,
some to haematologists for evaluation and others to various
specialties depending on sites of LA and associated clinical
features. In some cases, this could lead to delays in diagnosis,
resulting in increased anxiety among patients and further
postponement in commencing definitive treatment.
Royal Marsden Hospital (RMH) is a tertiary referral compre-
hensive cancer centre. Patients are normally referred from
secondary referral hospitals after a diagnosis of cancer has been
made. However, in an attempt to overcome the aforementioned
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problems in the referral pathway for patients with LA, a lymph
node diagnostic clinic (LNDC) was set up at our institution. The
primary aim was to reach rapid diagnosis in patients with LA using
a concerted multidisciplinary approach. Preliminary results on the
first year’s activity of this clinic have been reported previously
(Gregory et al, 2000). This paper reports on the first consecutive
550 patients referred between 1996 and 2001 to our lymph node
diagnostic clinic.
SETTING AND METHOD
Royal Marsden Hospital serves a local population of 2.2 million
residents. General practitioners (GPs) from 151 practices within
five local health authority regions referred patients to the LNDC.
Table 2 shows the demographics of the local population. The
LNDC was set up to run alongside existing clinics. Effectively this
service was provided 4 days per week. Invitation letters were sent
to GPs who had other cancer patients under follow-up at our
institution. Referrals were accepted directly from GPs for patients
with unexplained lymphadenopathy. Aside from lymphadenopa-
thy, some patients were referred for ‘lumps’ in extranodal sites.
Patients were initially assessed by a medical team comprising
medical oncologists and research nurses. The lead clinician (DC)
supervised the operation of the clinic during the entire study
period. According to clinical presentations, the following investi-
gations were carried out as appropriate: haematological assays
including complete blood count, erythrocyte sedimentation rate
and peripheral blood film; biochemistry profiles including serum
electrolytes, urea, creatinine, bilirubin, total protein, serum
albumin, liver transaminases and alkaline phosphatases, lactate
dehydrogenase (LDH), immunoglobulins, b2 microglobulin, plas-
ma and urine electrophoresis; bacterial, viral and parasitic
serology and culture; imaging including chest X-ray (CXR),
ultrasound (US), computed tomography (CT) and magnetic
resonance imaging (MRI); fine-needle aspiration and lymph node
biopsy. A written guideline for investigations was available in the
Royal Marsden Hospital Lymphoma Unit Clinical Guidelines
(Protocols and Policies) document.
Fine-needle aspirations were carried out on clinically suspicious
malignant lymph nodes. Fine-needle aspiration cytology (FNAC)
findings were graded from C0 to C5 according to traditional
cytomorphological methods (Trott, 1985). Definitions of C0– C5
are shown in Table 8. For lymph nodes that were clinically very
suspicious or cytological grades C3– C5, a formal lymph node
biopsy would be performed after appropriate surgical assessment.
Exceptions were cases where FNAC was diagnostic of carcinoma
(C5) and primary sites were readily identified. Lymph node
biopsies were carried out by head and neck, breast, plastic or
general surgeons, depending on sites of lymphadenopathy.
All patients returned to the LNDC to receive the results of
investigations. Patients diagnosed to have lymphoma were
managed within the lymphoma unit. Patients with malignancies
other than lymphoma were referred internally to other appropriate
units. Patients with non-neoplastic diagnoses that required specific
medical treatment were referred to the appropriate specialty at
another hospital. Other patients with benign reactive lymphadeno-
pathy or self-limiting diseases were reassured and discharged from
the LNDC. On some occasions, several clinic visits at variable time
intervals were required to ensure resolution of symptoms and
lymphadenopathy before formal discharge from the LNDC. All
discharged patients were advised to return to the LNDC if the
lymph node(s) enlarged or there was appearance of new lymph
node(s).
Details of patients’ demographics, clinical presentations, labora-
tory and imaging results, final diagnosis and subsequent manage-
ment were collected prospectively in the lymphoma research
databases. In addition, all case notes and investigation results from
all patients were available in our hospital electronic patient record
(EPR) system. To ensure high-quality data collection, all patients’
data recorded in the database in this series were cross-referenced
with EPR by two of the investigators (MK and IC) independently.
Discrepancies were verified with patients’ written notes if
necessary and the database was appended accordingly. A single
cytopathologist (PT) reviewed all FNAC, and a single histopathol-
ogist (AW) reviewed all lymph node biopsies where a final
diagnosis of lymphoma was made.
STATISTICAL CONSIDERATIONS
Descriptive statistics were used for the epidemiology of lympha-
denopathy in this series. The date of malignant diagnosis was
defined as the date of FNAC reporting in carcinoma and histology
reporting in lymphoma. The time from initial referral to date of
first definitive treatment (either chemotherapy or radiotherapy)
was determined for Hodgkin’s disease and diffuse large B-cell non-
Hodgkin’s lymphoma (NHL) as these are the two large subgroups
of patients who would require immediate treatment.
Stepwise logistic regression models were constructed using a
binary outcome specification for the presence or absence of
malignancy in lymph nodes. The independent variables included
in the analysis were age, gender, ethnicity, site and number of
regions of lymph nodes and whether LA had a bilateral
distribution. Number, size and texture of lymph nodes were
subject to considerable interobserver variation and therefore not
used as predictive factors in the multivariate models. Age was used
as a continuous variable. Ethnicity was divided into white or non-
white categories. Sites of presenting peripheral lymph nodes were
grouped into cervical, supraclavicular, axillary, inguinal or X2
regions of lymph nodes. Since cervical lymphadenopathy was the
most common site of lymph nodes in this series, multivariate
adjusted risk ratios (RR) were estimated with the RR for cervical
region set at 1. The relative importance of predictive factors was
measured by the Wald test with each predictive factor in the
stepwise logistic regression model. The threshold for inclusion in
the multivariate model was set at Po0.05.
Sensitivity, specificity, positive and negative predictive values
and accuracy of ultrasound and FNAC as tools for diagnosing
malignancy were determined. Accuracy was defined as the
proportions of true positives and true negatives in the total
number of investigations performed.
Table 1 Five-year relative survival of common cancers
Breast
cancer (%)
Lung
cancer (%)
Colorectal
cancer (%)
Non-Hodgkin’s
lymphoma (%)
Hodgkin’s
disease (%)
England and Wales 68 6 39 45 75
Europe 73 11 55 48 75
USA 86 14.5 61 53 83
Data adapted from: SEER Cancer Statistic Review, 1973–1998; Cancer Survival Trends in England and Wales 1971–1995.
Lymph node diagnostic clinic
I Chau et al
355
British Journal of Cancer (2003) 88(3), 354 – 361& 2003 Cancer Research UK
C
li
n
ic
a
l
Data analysis was performed using SPSS version 10.1.4 (SPSS
Inc., Chicago, IL, USA). All analyses were carried out in October
2001 on an ‘intention to assess’ basis.
RESULTS
Between December 1996 and July 2001, 550 patients were referred
to the lymph node diagnostic clinic. Table 2 shows the baseline
demographics of the patients referred. The median age was 40
years (range 14– 90). Each general practice referred a median of
two patients (range 1– 25). Figure 1 shows the time between receipt
of initial referral letter and first clinic visit. The median time for
this period was 6 days (including weekends and public holidays).
In total, 413 patients (75.1%) were seen within 1 week of referral
and 531 (96.5%) were seen within 2 weeks. All patients were
offered a clinic appointment within 2 weeks. Those patients who
were seen more than 2 weeks from referral did not attend their first
offered clinic appointment. Six patients failed to attend their
appointments. One patient attended the initial visit, but no follow-
up data were available.
Ninety-five patients (17.3%) were found to have malignant
disease (Table 3). The median time from the first clinic visit to
establishment of malignant diagnosis was 15 days (Figure 1).
Ninety-eight per cent of patients received their malignant
diagnosis within 2 months. Only two patients fell outside this
time period. The first patient had a delay in lymph node biopsy
because of social reasons, and in the second patient the reason for
the delay in biopsy was unknown.
Of the 19 patients diagnosed with Hodgkin’s disease, 18 received
induction chemotherapy and one received single modality radio-
therapy. One patient received chemotherapy abroad after diag-
nosis, and therefore the date of first treatment could not be
determined. The median time between date of diagnosis and date
of first definitive treatment (chemotherapy or radiotherapy) was
14 days (Figure 1). Of the 18 patients diagnosed with diffuse large
B-cell lymphoma, 17 patients received induction chemotherapy
and one received single modality radiotherapy. The median time
between date of diagnosis and date of first definitive treatment
(chemotherapy or radiotherapy) was 17.5 days (Figure 1).
Twenty-one patients had benign tumours confirmed on
histology (Table 3). One hundred and thirty-nine patients had
non-neoplastic disease with a recognised clinical diagnosis as the
cause of their lymphadenopathy or ‘lumps’ (Table 4). Figure 2
summarises the diagnostic pathway of all patients.
Table 5 shows the distribution of the presenting lymph node
sites for the whole cohort. Eighty patients (14.5%) had ‘lumps’ in
extranodal sites. These lumps included thyroid, cutaneous, facial
and breast lumps.
When multivariate logistic regression analysis was performed in
our cohort, the following factors were highly significant predictors
for malignant lymphadenopathy: male gender, increasing age,
white ethnicity, supraclavicular lymph nodes and X2 regions of
lymph nodes (Table 6). Extranodal ‘lumps’ had significantly low
risk for malignancy. For each 10-year increase in age, the increase
in risk of malignancy was 1.64 (95% CI 1.44–1.88). This model has
a sensitivity of 30.5%, a specificity of 97.1% and an accuracy of
85.6%.
Ultrasound (US) scans of clinically suspicious lymphadenopathy
were performed in 154 patients (28%). One hundred and three
patients had normal US findings and all of them had nonmalignant
diseases. Abnormal US findings were seen in 51 patients. These
findings correctly identified five benign tumours, 11 malignant
tumours and 30 non-neoplastic causes of LA. Ultrasound
incorrectly raised suspicion of malignancy in only five patients.
In our series, US as a diagnostic tool for detecting malignancy gave
an accuracy of 97% (Table 7).T
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CT scans were carried out in 132 patients in which 107 were
abnormal. However, CT scans were often carried out as part of the
staging in patients who had been diagnosed with malignancies
rather than as primary diagnostic investigations.
Fine-needle aspiration cytology of palpable lymph nodes was
performed in 289 patients (52.5%) (Table 8). Fifteen patients with
lymphadenopathy highly suspicious of malignancy were referred
directly for lymph node biopsy. Seventy-seven out of 95 patients
(81.1%) with malignancies had fine-needle aspirations performed.
Within this group of 77 patients, 38 (49.3%) had FNAC reported as
between C3 and C5, but 35 (45%) had FNAC reported to show no
malignant cells (C2). In this latter group with false-negative results,
83% had lymphoid malignancies. Two patients had FNAC reported
as C5, but turned out to have benign conditions after excision. The
first was a 39-year-old male smoker with parotid swelling.
Cytology was reported as probable salivary adenoid cystic
carcinoma. Subsequent superficial parotidectomy revealed a
pleomorphic adenoma. The second patient with submandibular
swelling revealed reactive lymph nodes with no evidence of
malignancy after selective neck dissection.
Two hundred and ten patients with nonmalignant processes had
FNAC performed. Five patients had FNAC showing C3 and
proceeded to formal excision biopsy. Two displayed reactive
lymphadenopathy of unknown cause. Two patients had acute
toxoplasmosis with concordant changes on biopsy. One patient
had caseating granulomata on biopsy and tuberculosis was
confirmed. In our series, FNAC as a diagnostic tool for detecting
malignancy gave an accuracy of 84% (Table 7).
Two hundred and seven patients (37.6%) were referred for
lymph node biopsy. Excision biopsies were performed in 182 cases.
One patient declined biopsy and 24 patients did not proceed to
biopsy after referral. The latter was in general because of resolution
of lymphadenopathy between referral and biopsy dates. Eighty-
seven patients with malignancy had formal tissue biopsy
performed. For those who did not have formal histology, three
were diagnosed with FNAC of C5 and tumour masses were seen in
lung or thyroid on imaging. Two patients were diagnosed on bone
marrow biopsy. One elderly woman suffered from severe comorbid
conditions precluding further investigations. One patient had a
diagnosis of lymphoma made clinically in another hospital after
refusing further investigations at our institution. One patient chose
to seek alternative therapy from a religious group. At autopsy, a
diagnosis of sarcoma was confirmed.
Fifty-two out of 120 patients (43%) with normal/absent
lymph nodes and 16 out of 168 patients (10%) with benign
reactive lymphadenopathy were discharged from the clinic on
their initial visits after reassurance. The remaining patients
with normal/absent lymph nodes or benign reactive lympha-
denopathy underwent a period of observation before formal
discharge.
Timepoint Time period Median (days) Range (days) Interquartile range (days) 
A Time from receiving initial referral letter to first clinic visit 0−100 2−7
B Time from first clinic visit to establishment of malignant diagnosis 15 0−121 8−22.5
C Time from first clinical visit to histological diagnosis of HD 21 7−97 16.5−27.5
D Time from first clinical visit to histological diagnosis of DLBCL 24 9−58 12.8−29.8
E Time from date of diagnosis to date of first definitive treatment for HD 14 0−133 5.5−17
F Time from date of diagnosis to date of first definitive treatment for 
DLBCL 
17.5 1−224 8.8−39.8
G Time from receiving initial referral letter to date of first definitive 
treatment for HD
35 7−142 24.8−42.8
H Time from receiving initial referral letter to date of first definitive 
treatment for DLBCL
39 14−253 30−58
550 patients 
included in 
the study 
544 patients 
assessed in 
clinic 
95 patients
diagnosed
with 
malignancy
19 patients
diagnosed
with HD
18 patients
diagnosed 
with 
DLBCL 
Definitive 
treatment
Definitive 
treatment
A 
F 
E
B
D
C
G
H
6
Figure 1 Time period from referral to diagnosis for the whole study cohort and treatment for Hodgkin’s disease (HD) and diffuse large B-cell non-
Hodgkin’s lymphoma (DLBCL). Median, range and interquantile range are quoted. As median values are quoted, time point G does not equal the sum of the
median values of A and C and E. Similarly, time point H does not equal the sum of the median values of time points A and D and F.
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DISCUSSION
A comprehensive review of the epidemiology and diagnostic work-
up of 550 patients referred to our lymph node diagnostic clinic was
undertaken. Patients were assessed in a timely fashion with a
median time of 6 days between receipt of the referral letter and the
first clinic visit, and all patients were offered an appointment
within 2 weeks. Malignancies were diagnosed with a median time
of 15 days from the patients’ initial visits, and those with
potentially curable cancers such as Hodgkin’s disease and diffuse
large B-cell lymphoma completed their staging investigations and
commenced their definitive treatment in just over 2 weeks after
diagnosis.
The poorer cancer survival in England compared to other
European countries and the USA has been attributed to the more
advanced stage of disease by the time patients are treated and the
prolonged time taken in hospitals to progress from the first
appointment through diagnostic tests to treatment (Department of
Health, 2000b). A multidisciplinary lymph node diagnostic clinic
therefore has the advantage of concentrating expertise, facilitating
investigations and ensuring prompt commencement of appro-
priate treatment. In particular, considering the diversity of causes
of lymphadenopathy, patients with malignant disease in our series
were able to reach their diagnosis in just over 2 weeks. No other
studies investigating lymphadenopathy have reported this timing.
A GP in England, with an average list size of 2000 patients, will
only see one or two new patients with lung cancer, one with breast
cancer and one with colorectal cancer per annum. For NHL, a GP
may see one case every 4 years, and with Hodgkin’s disease, one
case every 20 years (Department of Health, 2000a). The relatively
few cases seen by individual GPs makes it difficult to identify those
patients at highest risk.
The NHS Cancer Plan set milestones for all patients to be treated
within 2 months of urgent referral and within 1 month of diagnosis
by 2005 (Department of Health, 2000b). These targets were
achieved in our series with HD and diffuse large cell NHL. The
median time between initial referral and first treatment was just
over 7 weeks in our series. This encompassed the time required for
diagnosis, imaging for staging, lymph node and bone marrow
biopsy and histological interpretations. In our series, this time
period was not determined for other lymphoma subtypes and solid
tumours as a wide spectrum of treatment approaches are possible.
Sometimes an observation period may be adopted in the case of
follicular lymphoma and chronic lymphocytic leukaemia. One
Table 3 Diagnoses of neoplasm
Diagnosis Number
Lymphoproliferative disorders n=62
Hodgkin’s disease 19
Diffuse large B-cell lymphoma 18
Follicular lymphoma 10
B-chronic lymphocytic leukaemia 4
Mantel cell lymphoma 3
T-cell lymphoma 3
Small lymphocytic lymphoma 3
Post-transplant lymphoproliferative disorder 1
Lymphoma unknown subtype 1
Metastatic tumours n=29
Head and neck squamous cell carcinoma 10
Squamous cell carcinoma of oesophagus 1
Breast 3
Melanoma 3
Prostate 2
Nonsmall cell carcinoma of lung 2
Small cell carcinoma of lung 2
Thyroid 2
Seminoma 1
Unknown primary (two squamous cells, one small cell) 3
Other malignant tumours n=4
Myofibroblastic tumour 1
Myeloproliferative disease 1
Sarcoma 1
Unknown 1
Benign tumours n=21
Pleomorphic adenoma 10
Warthin’s adenolymphoma 4
Schwannoma 3
Thyroid adenoma 3
Carotid body tumour 1
Table 4 Miscellaneous non-neoplastic diseases
Diagnosis Number
(total n=139)
Infections n=47
Bacterial infections Total=19
Tuberculosis 12
Streptococcus 2
Corynebacterium 1
Moxarella 1
Bartonella 3
Viral infections Total=11
Human immunodeficiency virus 4
Epstein–Barr virus 5
Cytomegalovirus 1
Hepatitis C 1
Fungal/protozoal/parasitic infestations Total=17
Toxoplasmosis 15
Pediculosis/dermatophytosis 2
Immune-mediated injury disorders Total=13
Lupus erythematosus 6
Sarcoidosis 6
Rheumatoid arthritis 1
Primary skin diseases Total=5
Others Total=73
550 patients 
included in the 
study 
Six patients never attended 
their appointments. One
patient had no follow up
543 patients 
45 patients had no
palpable lymph-
adenopathy.  75 had 
normal palpable lymph 
nodes.
423 patients
95 patients
had
malignant
tumours
21 patients
had benign
tumours
168 patients
had benign
reactive
lymph-
adenopathy
139 patients
had 
miscellan-
eous non-
neoplastic
diagnoses
Figure 2 Diagnostic pathway for the whole study cohort.
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other study has reported this time period between initial referral
and first treatment in lymphoma (Summerfield et al, 2000). Eighty-
eight patients presented between 1997 and 1999 to three
institutions in the UK were assessed. The average delay from GP
referral to hospital appointment was 3.9 weeks. The average
diagnostic delay was 2.8 months and treatment delay was 1.2
months. Thus, an average of more than 21 weeks was required for
this cohort of patients to progress from initial referral to first
treatment. This time period was three times longer than that
achieved with our LNDC.
Nevertheless, a time period of 7 weeks from initial referral to
first definitive treatment still leaves room for improvement. A
retrospective national survey in the UK showed that apart from
breast and ovarian cancer, no other major cancer type patients
received first definitive treatment within a median of 7 weeks even
when the referral was urgent (Spurgeon et al, 2000). A recent study
in Canada showed that the median waiting time for 1456 patients
undergoing cancer surgery was 37 days and 37.2% of patients were
judged by their surgeons to have had an inappropriate wait
(Simunovic et al, 2001). A study in patients with lung cancer has
reported that only 32.4% of patients received definitive treatment
within 8 weeks of the first hospital visit (Melling et al, 2002) in
comparison with 75% of patients with diffuse large B-cell NHL and
95% of patients with HD in our series. In two other studies in
Canadian breast cancer patients, it was found that the median
time from screening examination to diagnosis was 3.7 weeks
(Olivotto et al, 2001) and the median time from diagnosis to
breast cancer surgery was 4.9 weeks (Mayo et al, 2001). However,
patients in these studies were already identified as suspected
malignancies, and were therefore not comparable to those
presented to our LNDC who were referred to evaluate lymp-
hadenopathy of unknown aetiology not necessarily of malignant
origin.
The impact of delay in diagnosis and treatment on survival is a
controversial area. A systematic review in breast cancer showed
that delays of 3 months or more had 12% worse 5-year survival
compared to those with shorter delays (Richards et al, 1999),
although another large study did not find such an association and
was not included in the systematic review (Sainsbury et al, 1999).
Indeed, this latter study found that patients with a delay of less
Table 5 Presenting lymph node regions
Lymph node
regions
Number of patients
Total n=550 (%)
Number of patients with
malignant diseasesa
Total n=95 (%)
Head and neck (level I–III and V) 254 (46.2) 35 (13.8)
Supraclavicular (level IV) 35 (6.4) 12 (34.3)
Axilla 53 (9.6) 8 (15.1)
Inguinal 41 (7.5) 7 (17.1)
X2 regions 87 (15.8) 30 (34.5)
Extranodalb 80 (14.5) 3 (3.8)
aMalignancy refers to presenting lymph node regions in patients with proven malignancy. Percentage refers to
the number of malignant nodes over the total number of patients with lymph nodes in a particular region. For
example: for head and neck, 35 out of 254 patients gives 13.8%. bExtranodal denotes ‘lumps’ not present in the
peripheral palpable lymph node regions.
Table 6 Multivariate logistic regression model predicting malignancy in
patients with lymphadenopathy (LA)
95% confidence interval
Predictive
factors Significance
Risk
ratio
Lower
limit
Upper
limit
Age Po0.001 1.05 1.04 1.07
Male sex Po0.001 2.72 1.63 4.56
Ethnicity–White P=0.02 3.01 1.19 7.6
Supraclavicular fossa LA P=0.004 3.72 1.52 9.12
X2 regions of LA Po0.001 6.41 2.82 14.58
Extranodal sites P=0.03 0.24 0.07 0.83
Table 7 Accuracy of investigations to detect malignancy
Tests No. Sensitivity (%) Specificity (%)
Positive predictive
value (%)
Negative predictive
value (%) Accuracy (%)
Ultrasound 154 100 97 69 100 97
Fine-needle aspiration 289 49 97 84 84 84
Table 8 Fine-needle aspiration cytology (FNAC)
Number (n=289)
FNAC
Benign
tumours
Malignant
tumours
Nonmalignant
disease
C0 4 4 22
C1 10
C2 14 35 155
C3 1 5
C4 14
C5 1 23 1
C0 denotes a sample as insufficient, occasionally containing no cells at all. C1 has scant
normal cells present that are too few to characterise. C2 contains normal cells that
are not suspicious for malignancy. C3 displays cells, which, though suspicious, are not
classifiable. C4 indicates a high probability of malignancy with inconclusive subtype. C5
is diagnostic of a particular specified malignancy.
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than 30 days between GP referral and treatment had worse survival
than patients in any other time period, a paradoxical finding also
illustrated in endometrial cancer (Crawford et al, 2002). However,
this may reflect the cancer biology – a more aggressive clinical
picture would prompt higher suspicion for malignancy and a
shorter starting time for the treatment of more advanced disease
which has a worse outcome. Other studies evaluating diagnostic
and treatment delays in other cancers and survival were
inconclusive, but they suffered from small sample sizes, and
therefore could not detect small but clinically meaningful survival
differences (Norum, 1995; Roncoroni et al, 1999; Bozcuk and
Martin, 2001; Jensen et al, 2002). Assessing the impact of delay in
diagnosis and treatment on survival will therefore require
continuing research effort.
In the primary care setting, the prevalence of malignancy in
patients with LA was between 0 and 1.3% (Allhiser et al, 1981;
Williamson Jr, 1985; Fijten and Blijham, 1988). Our malignancy
pick-up rate of 17.3% was, however, similar to that found in
another series from Greece (Vassilakopoulos and Pangalis,
2000). Other solid tumour one-stop clinics reported malignancy
pick-up rates of 3– 10% (Gui et al, 1995; Berry et al, 1998; Toomey
et al, 1998; Lamah et al, 2000; Patel et al, 2000). Of note, relative to
other lymphomas, a higher than anticipated incidence of
Hodgkin’s disease was seen in our series. All but one had nodular
sclerosing histological subtype and the majority of patients were
young adults. Our LNDC provided a gateway whereby young
adults with this highly curable malignancy could be swiftly
diagnosed.
Our multivariate logistic regression model identified increasing
age, male gender, white ethnicity and site of lymph nodes as
independent predictive factors for malignancy. Age has previously
been recognised as the most important factor in predicting
whether LA is due to a benign or malignant process (Lee et al,
1980). When one considers malignancies presenting with periph-
eral lymphadenopathy, there is a male predominance. Females are
also more likely to consult primary care physicians and use
diagnostic services compared to males (Bertakis et al, 2000)
although the complaint may not necessarily be of a sinister nature.
This may partly explain why males have an increased risk for
malignancy in our series. Supraclavicular and generalised lym-
phadenopathy were two other significant predictors for malig-
nancy in our series. Although supraclavicular lymph nodes were an
infrequent finding in our cohort, they are made up of the highest
proportion of malignant nodes. In a large series of supraclavicular
fossa swelling or lymph node fine-needle aspirations, 55% of
309 aspirates were found to be malignant (Ellison et al, 1999).
The presence of supraclavicular and generalised lymphadeno-
pathy should therefore alert the clinician to the possibility of
malignancy.
An algorithm for evaluating a patient with lymphadenopathy
has been proposed by Greenfield and Jordan (1978), although
this has been criticised as impractical, time-consuming and
expensive in the primary care setting (Williamson Jr, 1985). A
less aggressive approach making use of an adequate observation
period has been suggested (Williamson Jr, 1985). Two groups have
reported decision-making models that would identify more
precisely those patients who should have a biopsy (Slap et al,
1986; Vassilakopoulos and Pangalis, 2000). The study by
Vassilakopoulos et al evaluated 475 patients with lymphadeno-
pathy in a haematology unit in Greece (Vassilakopoulos and
Pangalis, 2000). A mathematical model was developed using six
variables – lymph node size, location (supraclavicular or
nonsupraclavicular), age (440 years or p40 years), texture
(soft/semihard or hard), tenderness and generalised pruritus.
Ninety-six per cent of those who required biopsy were correctly
classified by this model.
It has been accepted that cross-sectional imaging has a higher
accuracy than palpation in the diagnosis of neoplastic lymphade-
nopathy. The relative accuracy of each modality, however, is an
area of continuing study (Kaji et al, 1997). Ultrasound evaluation is
best suited for examining superficial lymph nodes because it is
inexpensive, easy to perform, has no ionising radiation and can
guide fine-needle aspiration at the time of examination. In
addition, the recent development of Doppler sonography technol-
ogy allows assessment of changes in nodal blood flow in order to
differentiate metastatic from nonmetastatic nodes (Wang et al,
2001). A recent study showed that a combination of grey-scale and
power Doppler sonography assessing internal architecture of the
node may be superior to CT in differentiating metastatic from
nonmetastatic nodes in the neck (Sumi et al, 2001). In our series,
US examination had 100% sensitivity and 96% specificity for
malignant nodes.
Fine-needle aspiration cytology has been accepted as a rapid,
minimally invasive and accurate method for the initial evaluation
of LA. Although the accuracy of diagnosing metastatic carcinoma
in lymph nodes by fine-needle aspirations is in excess of 90%
(Pangalis et al, 1993; Steel et al, 1995; Cha and Goates, 1996;
Prasad et al, 1996; Nasuti et al, 2000), the accuracy of diagnosing
primary lymphoma by fine-needle aspirations is only about
72% (Steel et al, 1995). However, with ancillary studies such as
immunocytochemical phenotyping and/or flow cytometry, the
accuracy of diagnosing haematopoietic conditions has been
improved considerably (Nasuti et al, 2000; Liu et al, 2001). In
our series, a false-negative rate of 13.5% in FNAC was seen,
mostly in lymphoid malignancies. A false-positive rate of 2.4%
in our series for malignancy was high compared with other
studies (0.2– 0.9%) (Steel et al, 1995; Nasuti et al, 2000). However,
the proportion of nondiagnostic specimens of 10.4% was
similar to another study (Nasuti et al, 2000). As fine-needle
aspirations are operator-dependent, this shortfall in our FNAC
accuracy could be partly explained by the lack of dedicated
cytopathologists performing fine-needle aspirations at our clinic.
Many studies had experienced cytopathologists at the clinic to
provide immediate assessment. Adequate sampling and/or triage
for further studies could thus be ensured. Many of these series,
however, had a significant patient selection bias consisting entirely
of patients with malignant lesions (Steel et al, 1995; Nasuti et al,
2000; Liu et al, 2001); therefore, results were strictly not
comparable with ours.
The limitation of our series stems from the patients referred.
Although GPs were encouraged to refer any cases of unexplained
lymphadenopathy, there may be an inherent selection bias in the
referral pattern depending on suspicion on malignancy. In
addition, an attempt was not made to determine the differences
in the time required for the diagnosis of patients referred outside
the LNDC pathway and those diagnosed in our LNDC. However,
such a comparison is problematic as firstly there might be different
referral behaviour across different time periods because of, for
example, the government initiative of the ‘2-week rule’ for urgent
referral (Department of Health, 2000a). As the median number of
patients referred per GP was only two, the consistency in the
referral pattern across different time periods was therefore not
assessable. Secondly, there may be an inherent bias of why a GP
chose a particular route of referral. A randomised study of a
conventional referral pathway and LNDC would be desirable but
difficult to conduct as there is no consistency in the conventional
referral pathway.
In conclusion, a multidisciplinary lymph node diagnostic clinic
enables a rapid, concerted approach to evaluate a common medical
problem. Patients with malignant diseases were able to receive
their diagnoses in a timely fashion. Our clinic provides a
diagnostic service delivery model to which one could compare
future health service innovations. Further research is essential to
integrate diagnostic services with staging investigations and
treatment delivery, and this may in future lead to improved
survival in these patients.
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